Silkrute

Silk Road Medical is a medical technology company focused on reducing the risk of stroke through its proprietary Transcarotid Artery Revascularization (TCAR) procedure. The company's flagship products, the ENROUTE Transcarotid Neuroprotection System and the ENROUTE Transcarotid Stent System, allow for a minimally invasive approach to treating carotid artery disease by reversing blood flow during the procedure to prevent emboli from reaching the brain. This approach combines the surgical principles of neuroprotection with the less invasive advantages of endovascular stenting. In September 2024, the company was acquired by Boston Scientific for approximately $1.16 billion, integrating its stroke prevention portfolio into Boston Scientific's peripheral interventions division.